Contact this trialFirst, we need to learn more about you.
GLP-1 Receptor Agonist
Semaglutide for HIV-Associated Lipohypertrophy
Recruiting2 awardsPhase 2
Cleveland, Ohio
This trial will assess the effect of semaglutide on visceral and ectopic fat in people with HIV, as well as changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.